Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Japan ETF (EWJ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

iShares MSCI Japan ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Japan ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI Japan ETF trades at $97.87, while Zimmer Biomet Holdings Inc trades at $95.96 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while iShares MSCI Japan ETF pays none, and iShares MSCI Japan ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.

EWJZBH
Sector
Broad Market / FactorHealth
52-Week High
$96.97$107.71
52-Week Low
$77.93$79.58
Market Cap
$18.55B
Enterprise Value
$25.61B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Japan ETF

EWJ (iShares MSCI Japan ETF) trades at $98.12, up 2.16% with strong bullish technical signals from moving averages. The ETF benefits from recent U.S.-Japan currency intervention supporting the yen, while facing headwinds from Japan's inflation dynamics and export pressures. Technical indicators show overbought conditions with RSI at 84.79, suggesting potential near-term consolidation.

Outlook remains cautiously optimistic as Japanese equities respond to policy support, though currency volatility and economic uncertainty present risks. The fund's exposure to Japan's export sector faces challenges from yen strength, while domestic stimulus measures could provide upside potential for consumer-focused holdings.

Zimmer Biomet Holdings Inc

ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.

The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Japan ETF

EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.

Read more on EWJ

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH